Pacira BioSciences (PCRX) Stock Forecast, Price & News

Pacira BioSciences (NASDAQ:PCRX) Frequently Asked Questions

Is Pacira BioSciences a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pacira BioSciences stock.
View analyst ratings for Pacira BioSciences or view top-rated stocks.

When is Pacira BioSciences' next earnings date?

Pacira BioSciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Pacira BioSciences.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) released its earnings results on Wednesday, May, 4th. The company reported $0.64 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.83 by $0.19. The business had revenue of $157.99 million for the quarter, compared to analysts' expectations of $155.08 million. Pacira BioSciences had a net margin of 6.62% and a trailing twelve-month return on equity of 15.17%. The business's revenue was up 32.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.37 earnings per share.
View Pacira BioSciences' earnings history.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences updated its first quarter 2022 earnings guidance on Tuesday, April, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $157.40 million-$158.40 million, compared to the consensus revenue estimate of $162.85 million.

What price target have analysts set for PCRX?

7 analysts have issued 1-year price objectives for Pacira BioSciences' stock. Their forecasts range from $60.00 to $96.00. On average, they anticipate Pacira BioSciences' stock price to reach $82.00 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price.
View analysts' price targets for Pacira BioSciences or view top-rated stocks among Wall Street analysts.

Who are Pacira BioSciences' key executives?

Pacira BioSciences' management team includes the following people:

• Mr. David M. Stack, Chairman & CEO (Age 72, Pay $1.59M) (LinkedIn Profile)
• Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 61, Pay $702.36k) (LinkedIn Profile)
• Ms. Kristen Williams J.D., Chief Admin. Officer & Sec. (Age 48, Pay $788.31k)
• Mr. Max Reinhardt, Pres of Rest of World (Age 51, Pay $850.16k) (LinkedIn Profile)
• Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 43)
• Mr. Charles Laranjeira, Chief Technical Officer (Age 56)
• Susan Mesco, Head of Investor Relations
• Mr. Anthony Molloy III, Esq., Chief Legal & Compliance Officer (Age 48)
• Mr. Richard Kahr, VP of HR
• Mr. Robert J. Weiland, Sr. VP of Alliance Management (Age 62)

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences CEO Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among Pacira BioSciences' employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pacira BioSciences' key competitors?

Some companies that are related to Pacira BioSciences include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of PCRX's competitors.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.32%), Baillie Gifford & Co. (4.68%), Renaissance Technologies LLC (4.10%), Loomis Sayles & Co. L P (2.85%), Stephens Investment Management Group LLC (2.56%) and Clearbridge Investments LLC (2.48%). Company insiders that own Pacira BioSciences stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends for Pacira BioSciences.

Which major investors are selling Pacira BioSciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Paulson & CO. Inc., Rock Springs Capital Management LP, Zurcher Kantonalbank Zurich Cantonalbank , Goldman Sachs Group Inc., Baillie Gifford & Co., AIA Group Ltd, and Candriam Luxembourg S.C.A.. Company insiders that have sold Pacira BioSciences company stock in the last year include Anthony Molloy, Charles A Reinhart III, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, and Roy Winston.
View insider buying and selling activity for Pacira BioSciences or view top insider-selling stocks.

Which major investors are buying Pacira BioSciences stock?

PCRX stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Lisanti Capital Growth LLC, Russell Investments Group Ltd., New York State Common Retirement Fund, Frontier Capital Management Co. LLC, and Loomis Sayles & Co. L P.
View insider buying and selling activity for Pacira BioSciences or or view top insider-buying stocks.

How do I buy shares of Pacira BioSciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $63.57.

How much money does Pacira BioSciences make?

Pacira BioSciences has a market capitalization of $2.89 billion and generates $541.53 million in revenue each year. The company earns $41.98 million in net income (profit) each year or $0.839990 on an earnings per share basis.

How many employees does Pacira BioSciences have?

Pacira BioSciences employs 697 workers across the globe.

What is Pacira BioSciences' official website?

The official website for Pacira BioSciences is www.pacira.com.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at (813) 553-6680, via email at [email protected], or via fax at 302-655-5049.